With the evolution of the Experimental Therapeutics Clinical Trials Network (ETCTN), the Johns Hopkins Translational Science Team (JHTST) expanded in 2016 by bringing 5 (now 6) Affiliate Organizations (AO) under our Lead Academic Organization (LAO) with the goal to enhance and accelerate our collective contribution to the drug development efforts of the NCI. We have organized a comprehensive and cohesive infrastructure that can conduct high-quality clinical trials evaluating novel anticancer agents, in combinations, in molecularly selected patient populations, or rare tumor sites. Our infrastructure stems from the need to be clinically efficient, regulatory compliant and scientifically rigorous in our approach as we collaborate as network members within the ETCTN. Our infrastructure consists of seven experienced NCI-designated Cancer Centers: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Emory Winship Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, Memorial Sloan Kettering Cancer Center, University of Virginia Cancer Center, and University of Wisconsin Carbone Cancer Center. This collection of Centers brings together many unique discovery strengths, diverse patient volumes, and locations both urban and rural. We will focus on 4 Specific Aims:
Aim 1 - To lead and maintain a clinical trial consortium that will support cancer clinical trials from Phase 1 initiation through proof-of- activity and foster seamless Phase 2 clinical development of NCI CTEP IND agents;
Aim 2 - To actively participate and engage disease-focused clinical investigators in the ETCTN by promoting accrual to a range of ETCTN studies led by other LAO/AO members;
Aim 3 - To incorporate and implement innovative correlative and biological laboratory studies in the context of or as eligibility for participation in early phase clinical studies that enhance our understanding of determinants of toxicity and response that will be used for further definitive practice-changing clinical trial evaluation;
and Aim 4 - To train the next generation of investigators in drug development. With 7 Centers within our Consortium, we anticipate no problem in meeting the grant metrics of 100 accruals per year, submitting enough LOI concepts to have 6 new studies approved each year, functioning as a network by having Disease-Focused Clinical Investigators champion ETCTN studies at each Site across disease sites, and to provide opportunities to engage and train early career investigators in drug development. We anticipate that our contributions within the ETCTN will impact the clinical care of cancer patients.

Public Health Relevance

Our Consortium will continue its long- standing contribution to the drug development efforts of the NCI by leveraging its collective experience, commitment to collaboration, and legacy of training young investigators to impact the clinical care of cancer patients. We promote inclusiveness of the many medical disciplines that are required to conduct innovative, informative, and insightful early phase clinical trials. We anticipate enhanced interactions with the National Clinical Trials Network to bring forward successes from the efforts of the ETCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
2UM1CA186691-06
Application #
9933680
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ivy, S Percy
Project Start
2014-03-13
Project End
2023-02-28
Budget Start
2020-05-01
Budget End
2023-02-28
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Liu, Tao; Ivaturi, Vijay; Sabato, Philip et al. (2018) Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11:435-443
Pietanza, M Catherine; Waqar, Saiama N; Krug, Lee M et al. (2018) Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. J Clin Oncol 36:2386-2394
Yeruva, Sri Lakshmi Hyndavi; Zhao, Fengmin; Miller, Kathy D et al. (2018) E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. NPJ Breast Cancer 4:1
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2017) A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 23:697-706
Siu, Lillian L; Ivy, S Percy; Dixon, Erica L et al. (2017) Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res 23:4950-4958
Knaus, Hanna A; Kanakry, Christopher G; Luznik, Leo et al. (2017) Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets 18:315-331
Nguyen, Doreen; Gocke, Christopher D (2017) Managing the genomic revolution in cancer diagnostics. Virchows Arch 471:175-194
Baik, Christina S; Rubin, Eric H; Forde, Patrick M et al. (2017) Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clin Cancer Res 23:4992-5002
Anagnostou, Valsamo; Yarchoan, Mark; Hansen, Aaron R et al. (2017) Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res 23:4959-4969

Showing the most recent 10 out of 49 publications